ADVERTISEMENT
4 /5 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Start-ups

UMass gene therapy spin-off Apic Bio launches

by Ryan Cross
January 18, 2019 | APPEARED IN VOLUME 97, ISSUE 3

 

Apic Bio, a spin-off from the University of Massachusetts Medical School, has raised $40 million in series A financing to develop gene therapies for people with the neurodegenerative disease amyotrophic lateral sclerosis (ALS) and a rare genetic disease called α-1 antitrypsin deficiency. Apic’s approach, developed at UMass, uses adeno-associated viruses to introduce a microRNA, which silences the mutant gene, along with instructions for a new, functional gene. Apic CEO John Reilly says the funds should get the programs through Phase II clinical studies.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment